780.4
-12.30 (-1.55%)
SENORES • 14 Nov, 2025 | 03:29 PM
Senores Pharmaceuticals Stock Performance
|
|
|
Senores Pharmaceuticals Company background
Founded in: 2017
Managing director: SWAPNIL JATINBHAI SHAH
Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the midmarket range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024.The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025.
Senores Pharmaceuticals Financial Highlights
Senores Pharmaceuticals reported a Q1FY26
revenue of ₹161.76 crore,
up 92.1% YoY,
with net profit increased
78.4% to ₹30.12 crore. For the full year FY2025–2026, revenue
reached ₹417.51 crore and profit touched at
₹58.34 crore. As of Sep '25, Senores Pharmaceuticals’s market capitalisation stood at ₹3,594.02 crores.
Shareholding as of Sep '25 shows promoters holding 45.8%, with FIIs at
4.3%, DIIs at 8.6%, and public at 41.3%.
Senores Pharmaceuticals Share Price Today
As of 15 Nov 2025, Senores Pharmaceuticals share price is ₹780.4. The stock opened at ₹792.7 and had closed at ₹792.7 the previous day. During today’s trading session, Senores Pharmaceuticals share price moved between ₹772.65 and ₹792.70, with an average price for the day of ₹782.67. Over the last 52 weeks, the stock has recorded a low of ₹435.25 and a high of ₹832.00. In terms of performance, Senores Pharmaceuticals share price has increased by 44.2% over the past six months and has increased by 24.38% over the last year.
Senores Pharmaceuticals Fundamental
Market Cap (in crs)
3,594.02
Face Value
10
Turnover (in lacs)
1,457.23
Key Metrics
Qtr Change %
15.6
Dividend yield 1yr %
0
Senores Pharmaceuticals Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Senores Pharmaceuticals Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
161.76 Cr | 137.99 Cr | 114.21 Cr | 103.02 Cr | 100.63 Cr |
Senores Pharmaceuticals Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
417.51 Cr | 217.34 Cr | 39.02 Cr | 14.63 Cr |
Senores Pharmaceuticals Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
30.12 Cr | 21.18 Cr | 17.97 Cr | 16.43 Cr | 13.04 Cr |
Senores Pharmaceuticals Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
58.34 Cr | 32.71 Cr | 8.43 Cr | 0.99 Cr |
Senores Pharmaceuticals Result Highlights
Result Summary
-
Senores Pharmaceuticals Ltd reported a 35.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 17350.6%.
-
Its expenses for the quarter were down by 40.3% QoQ and up 16791.2% YoY.
-
The net profit decreased 35.2% QoQ and increased 19154.5% YoY.
-
The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 4.6 during Q1FY26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Senores Pharmaceuticals Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
780.4
Current Price
Day EMA5
783.50
Day EMA10
781.00
Day EMA12
778.90
Day EMA20
769.10
Day EMA26
762.00
Day EMA50
736.90
Day EMA100
694.20
Day EMA200
622.20
Day SMA5
780.50
Day SMA10
784.20
Day SMA20
769.90
Day SMA30
752.80
Day SMA50
733.80
Day SMA100
687.50
Day SMA150
632.70
Day SMA200
613.90
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 91366 Rs | 194371 Rs |
Week Rs | 204224 Rs | 381858 Rs |
Month Rs | 181240 Rs | 423650 Rs |
Resistance & Support
781.92
Pivot
Resistance
First Resistance
791.18
Second Resistance
801.97
Third Resistance
811.23
Support
First Support
771.13
Second support
761.87
Third Support
751.08
Relative Strength Index
55.14
Money Flow Index
77.51
MACD
16.88
MACD Signal
18.32
Average True Range
27.51
Average Directional Index
34.39
Rate of Change (21)
9.20
Rate of Change (125)
57.31
Senores Pharmaceuticals Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
318.20 | 3,190.99 | 298.8 | 498.25 | 324.60 | -4.74% | -12.88% | -15.69% | -28.58% | 48.83% | 0.03% | 51.87 | 41.59 | 5.28 | |
230.78 | 2,845.53 | 225.13 | 464.75 | 240.37 | -0.47% | -3.16% | -45.25% | -42.86% | -29.82% | 0.35% | 45.19 | 41.59 | 2.26 | |
803.70 | 4,076.29 | 603.8 | 1997.4 | 798.20 | -4.50% | 10.95% | 2.30% | -44.20% | 93.69% | 0.00% | 56.55 | 41.59 | 3.04 | |
2,293.30 | 3,792.89 | 1835 | 2725 | 2,333.60 | -4.46% | -0.47% | 6.27% | 6.29% | 135.16% | 1.05% | 33.94 | 41.59 | 6.83 | |
466.10 | 3,281.61 | 444 | 922.25 | 469.60 | 1.30% | -0.97% | -18.66% | -47.85% | 19.90% | 0.00% | 38.93 | 41.59 | 1.35 | |
249.20 | 3,907.03 | 178 | 321.95 | 245.95 | 0.14% | -10.70% | 17.03% | 17.25% | 120.92% | 0.00% | 0.00 | 41.59 | 0.98 |
Senores Pharmaceuticals Share Price FAQs
What is Share Price of Senores Pharmaceuticals ?
Senores Pharmaceuticals share price is ₹780.4 in NSE and ₹778.85 in BSE as on 14/11/2025.
How has Senores Pharmaceuticals shares performed in the past ?
Senores Pharmaceuticals share price in the past 1-year return was 0. The Senores Pharmaceuticals share hit a 1-year low of Rs. 435.25 and a 1-year high of Rs. 832.
What is the market cap of Senores Pharmaceuticals ?
The market cap of Senores Pharmaceuticals is Rs. 3594.02 Cr. as of 14/11/2025.
What is the current P/E ratio of Senores Pharmaceuticals ?
The PE ratios of Senores Pharmaceuticals is 293.91 as of 14/11/2025.
What is the current PB ratio of Senores Pharmaceuticals ?
The PB ratios of Senores Pharmaceuticals is 5.02 as of 14/11/2025
What is the Mutual Fund shareholding in Senores Pharmaceuticals ?
The Mutual Fund Shareholding in Senores Pharmaceuticals was 3.54% at the end of 14/11/2025.
How to buy Senores Pharmaceuticals shares?
You can easily buy Senores Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Senores Pharmaceuticals ?
The 52-week high and low of Senores Pharmaceuticals share price is ₹832 and ₹435.25 as of 14/11/2025.
What is the EPS of Senores Pharmaceuticals ?
The earnings per share (EPS) of Senores Pharmaceuticals stood at 4.6 during Q1FY26.
Please be aware that Senores Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.
Invest in Senores Pharmaceuticals